Fig. 4From: Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trialBox plots of immunohistochemical evaluation. A–E The expression of CD4, CD8, CD20, CD38, and CD68 in tissues pre- and post- treatment. F The difference in CD20 expression pre- and post-treatment in patients with pCR/MPR and PPR/NPR. G Spearman’s correlation analysis of the difference in CD20 expression pre- and post-treatment with pathological response rates (p < 0.05, r = 0.75). (H–I) CD20 expression pre- and post-treatment in the patient with MPR (G) and NPR (I)Back to article page